Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Increased pulsatility index is associated with adverse outcomes in left ventricular assist device recipients

Z. Tucanova, P. Ivak, P. Wohlfahrt, M. Pol, D. Hlavacek, M. Konarik, O. Szarszoi, I. Netuka, J. Pitha

. 2021 ; 8 (5) : 4288-4295. [pub] 20210804

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003567

AIMS: Recipients of left ventricular assist devices (LVAD) are exposed to increased risk of adverse clinical events. One of the potential contributing factors is non-pulsatile flow generated by LVAD. We evaluated the association of flow patterns in carotid arteries and of increased arterial stiffness with death and cerebrovascular events in LVAD recipients. METHODS AND RESULTS: We analysed data from 83 patients [mean age 54 ± 15 years; 12 women; HeartMate II (HMII), n = 34; HeartMate 3 (HM3), n = 49]. Pulsatile and resistive indexes, atherosclerotic changes in carotid arteries (measured by duplex ultrasound), and arterial stiffness [measured by Endo-PAT 2000 as the augmentation index standardized for heart rate (AI@75)] were evaluated 3 and 6 months after LVAD implantation. Sixteen patients died during follow-up (27.3 months; interquartile range 15.7-44.3). After adjusting for the main variables examined, the pulsatility index measured at 3 months was positively associated with increased hazard ratios (HR) for death and cerebrovascular events [HR 9.8, 95% confidence interval (CI) 1.62-59.42], with HR increasing after adding AI@75 to the model (HR 18.8, 95% CI 2.44-145.50). In HM3 recipients, HR was significantly lower than in HMII recipients (HR 0.31, 95% CI 0.11-0.91), but the significance disappeared after adding AI@75 to the model (HR 0.33, 95% CI 0.09-1.18). CONCLUSIONS: The risk of death and cerebrovascular events in LVAD recipients is associated with increased pulsatility index in carotid arteries and potentiated by increased arterial stiffness. The same risk is attenuated by HM3 LVAD implantation, but this effect is weakened by increased arterial stiffness.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003567
003      
CZ-PrNML
005      
20220127150110.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ehf2.13537 $2 doi
035    __
$a (PubMed)34346192
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Tucanova, Zuzana $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, 140 21, Czech Republic $u Second Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Increased pulsatility index is associated with adverse outcomes in left ventricular assist device recipients / $c Z. Tucanova, P. Ivak, P. Wohlfahrt, M. Pol, D. Hlavacek, M. Konarik, O. Szarszoi, I. Netuka, J. Pitha
520    9_
$a AIMS: Recipients of left ventricular assist devices (LVAD) are exposed to increased risk of adverse clinical events. One of the potential contributing factors is non-pulsatile flow generated by LVAD. We evaluated the association of flow patterns in carotid arteries and of increased arterial stiffness with death and cerebrovascular events in LVAD recipients. METHODS AND RESULTS: We analysed data from 83 patients [mean age 54 ± 15 years; 12 women; HeartMate II (HMII), n = 34; HeartMate 3 (HM3), n = 49]. Pulsatile and resistive indexes, atherosclerotic changes in carotid arteries (measured by duplex ultrasound), and arterial stiffness [measured by Endo-PAT 2000 as the augmentation index standardized for heart rate (AI@75)] were evaluated 3 and 6 months after LVAD implantation. Sixteen patients died during follow-up (27.3 months; interquartile range 15.7-44.3). After adjusting for the main variables examined, the pulsatility index measured at 3 months was positively associated with increased hazard ratios (HR) for death and cerebrovascular events [HR 9.8, 95% confidence interval (CI) 1.62-59.42], with HR increasing after adding AI@75 to the model (HR 18.8, 95% CI 2.44-145.50). In HM3 recipients, HR was significantly lower than in HMII recipients (HR 0.31, 95% CI 0.11-0.91), but the significance disappeared after adding AI@75 to the model (HR 0.33, 95% CI 0.09-1.18). CONCLUSIONS: The risk of death and cerebrovascular events in LVAD recipients is associated with increased pulsatility index in carotid arteries and potentiated by increased arterial stiffness. The same risk is attenuated by HM3 LVAD implantation, but this effect is weakened by increased arterial stiffness.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a ateroskleróza $7 D050197
650    _2
$a ženské pohlaví $7 D005260
650    12
$a srdeční selhání $7 D006333
650    12
$a podpůrné srdeční systémy $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ivak, Peter $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, 140 21, Czech Republic $u Department of Physiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic $u Second Department of Surgery, Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Wohlfahrt, Peter $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Pol, Marek $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, 140 21, Czech Republic
700    1_
$a Hlavacek, Daniel $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, 140 21, Czech Republic $u Department of Physiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Konarik, Miroslav $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, 140 21, Czech Republic $u Institute of Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Szarszoi, Ondrej $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, 140 21, Czech Republic $u Department of Pathophysiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Netuka, Ivan $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, 140 21, Czech Republic $u Second Department of Surgery, Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pitha, Jan $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Centre for Experimental Medicine, Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 8, č. 5 (2021), s. 4288-4295
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34346192 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150107 $b ABA008
999    __
$a ok $b bmc $g 1751124 $s 1154716
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 8 $c 5 $d 4288-4295 $e 20210804 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace